French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Monday that it has obtained CE-marking for LUMED APSS, a clinical decision support system designed to enhance antimicrobial stewardship programmes and improve patient care.

Developed by Lumed, a Canada-based company acquired by bioMérieux in 2024, LUMED APSS aids infectious disease pharmacists and physicians in addressing antimicrobial overuse and resistance.

The software continuously evaluates treatments based on clinical data, supporting decisions such as de-escalation of therapy and switching to oral antibiotics when appropriate. The offering also includes training and implementation support for medical teams and AMS committees in hospitals.

LUMED APSS complements bioMérieux's digital health portfolio, BIOMÉRIEUX VISION SUITE, and is accompanied by the LUMED ZINC surveillance module, which helps prevent infections in healthcare settings.

Now CE-marked, LUMED APSS will be deployed across Europe, with global expansion planned in the near future.